Correction: Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer

Rok, strany: 2024, 509 - 509

Due to the delayed delivery of the request for a correction and the requirement from the Office of Zhejiang Chinese Medical University to standardize the institution's English translation, the editorial department of NEOPLASMA has issued a correction in response to the author's signed request: The affiliation of the first author has been changed from "Graduate School of Zhejiang University of Traditional Chinese Medicine" to "Graduate School, Zhejiang Chinese Medical University."

ISO 690:

Ying, X., Shi, Z., Shao, R., You, G., Song, Z. 2024. Correction: Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer. In NEOPLASMA, vol. 71, no.5, pp. 509-509. 0028-2685. DOI: https://doi.org/10.4149/neo_2024_231104N572COR

APA:

Ying, X., Shi, Z., Shao, R., You, G., Song, Z. (2024). Correction: Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer. NEOPLASMA, 71(5), 509-509. 0028-2685. DOI: https://doi.org/10.4149/neo_2024_231104N572COR

Vydavateľ: AEPress, Ltd.